Biogen (BIIB) Current Deferred Tax Assets (2010 - 2011)
Biogen (BIIB) recorded quarterly Current Deferred Tax Assets of $8.1 million in Q4 2011, down 92.78% quarter-over-quarter from $112.2 million in Q4 2010, and down 92.78% on a YoY basis from $112.2 million in Q4 2010.
Biogen (BIIB) Current Deferred Tax Assets (2010 - 2011) Analysis & Trends
Biogen's Current Deferred Tax Assets history runs 2 years deep, the most recent figure standing at $8.1 million for Q4 2011.
- In Q4 2011, Current Deferred Tax Assets fell 92.78% year-over-year to $8.1 million; the TTM figure through Dec 2011 stood at $8.1 million (down 92.78% YoY), while the FY2011 annual figure was $8.1 million, down 92.78% from the prior year.
- Current Deferred Tax Assets was $8.1 million for Q4 2011 at Biogen, down from $112.2 million in the prior quarter.
- In the past five years, Current Deferred Tax Assets ranged from a high of $112.2 million in Q4 2010 to a low of $8.1 million in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 8.10 Mn |
| Dec 31, 2011 | 8.10 Mn |
| Dec 31, 2010 | 112.20 Mn |
| Dec 31, 2010 | 112.20 Mn |